Johnson & Johnson’s Remicade Patent Invalidated
The Patent and Trademark Office sends notice rejection of the company’s Remicade patent.
Johnson & Johnson announced on Feb. 12, 2015 that the company had received a notice of further action from the United States Patent and Trademark Office (PTO) that PTO re-examined and rejected US Patent No. 6,284,471 (‘471) relating to Remicade (infliximab). The company has 60 days to respond to PTO. J&J stated in a press release that the patent, which expires in September 2018, is valid and the company will appeal the rejection.
A revocation of the patent could be good news for Hospira’s biosimilar Inflectra (infliximab), which is approved for use in Central and Eastern Europe and just received approval for use in West Europe. Celltrion, a partner of Hospira, also has a biosimilar version of infliximab, Remsima, which is currently being reviewed for use in the United States by FDA.
Source: Johnson & Johnson
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
